Literature DB >> 18596617

Amygdaloid metabotropic glutamate receptor subtype 7 is involved in the acquisition of conditioned fear.

Stephanie Siegl1, Peter J Flor, Markus Fendt.   

Abstract

The metabotropic glutamate receptor subtype 7 (mGluR7) is presynaptically located and modulates transmitter release. An earlier study from our group demonstrated that systemic administration of N,N'-dibenzyhydryl-ethane-1,2-diamine dihydrochloride (AMN082), a selective allosteric mGluR7 agonist, attenuates the acquisition of conditioned fear measured by fear-potentiated startle. Aim of this study was to explore whether this effect is mediated by the basolateral amygdala, a crucial brain structure for acquisition of conditioned fear. Therefore, AMN082 was locally injected into the basolateral amygdala of rats and the effects of these injections on the acquisition of conditioned fear was measured. Our data clearly show that intra-amygdala injection of AMN082 impairs fear acquisition. This finding demonstrates that amygdaloid mGluR7 controls the learning of conditioned fear.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18596617     DOI: 10.1097/WNR.0b013e328307f295

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  14 in total

Review 1.  Molecular mechanisms of fear learning and memory.

Authors:  Joshua P Johansen; Christopher K Cain; Linnaea E Ostroff; Joseph E LeDoux
Journal:  Cell       Date:  2011-10-28       Impact factor: 41.582

Review 2.  Fear conditioning, synaptic plasticity and the amygdala: implications for posttraumatic stress disorder.

Authors:  Amy L Mahan; Kerry J Ressler
Journal:  Trends Neurosci       Date:  2011-07-26       Impact factor: 13.837

Review 3.  Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders.

Authors:  N Singewald; C Schmuckermair; N Whittle; A Holmes; K J Ressler
Journal:  Pharmacol Ther       Date:  2014-12-27       Impact factor: 12.310

Review 4.  Metabotropic Glutamate Receptor 7 (mGluR7) as a Target for the Treatment of Psychostimulant Dependence.

Authors:  Xia Li; Athina Markou
Journal:  CNS Neurol Disord Drug Targets       Date:  2015       Impact factor: 4.388

Review 5.  Metabotropic glutamate 7 (mGlu7) receptor: a target for medication development for the treatment of cocaine dependence.

Authors:  Xia Li; Zheng-Xiong Xi; Athina Markou
Journal:  Neuropharmacology       Date:  2012-04-21       Impact factor: 5.250

6.  Fear-reducing effects of intra-amygdala neuropeptide Y infusion in animal models of conditioned fear: an NPY Y1 receptor independent effect.

Authors:  Markus Fendt; Hugo Bürki; Stefan Imobersteg; Kurt Lingenhöhl; Kevin H McAllister; David Orain; Doncho P Uzunov; Frederique Chaperon
Journal:  Psychopharmacology (Berl)       Date:  2009-07-17       Impact factor: 4.530

7.  Fear potentiated startle increases phospholipase D (PLD) expression/activity and PLD-linked metabotropic glutamate receptor mediated post-tetanic potentiation in rat amygdala.

Authors:  Balaji Krishnan; Michael T Scott; Sebastian Pollandt; Bradley Schroeder; Alexander Kurosky; Patricia Shinnick-Gallagher
Journal:  Neurobiol Learn Mem       Date:  2015-12-31       Impact factor: 2.877

8.  A genome-wide study of common SNPs and CNVs in cognitive performance in the CANTAB.

Authors:  Anna C Need; Deborah K Attix; Jill M McEvoy; Elizabeth T Cirulli; Kristen L Linney; Priscilla Hunt; Dongliang Ge; Erin L Heinzen; Jessica M Maia; Kevin V Shianna; Michael E Weale; Lynn F Cherkas; Gail Clement; Tim D Spector; Greg Gibson; David B Goldstein
Journal:  Hum Mol Genet       Date:  2009-09-04       Impact factor: 6.150

9.  Deep brain stimulation, histone deacetylase inhibitors and glutamatergic drugs rescue resistance to fear extinction in a genetic mouse model.

Authors:  Nigel Whittle; Claudia Schmuckermair; Ozge Gunduz Cinar; Markus Hauschild; Francesco Ferraguti; Andrew Holmes; Nicolas Singewald
Journal:  Neuropharmacology       Date:  2012-06-18       Impact factor: 5.250

Review 10.  HDAC inhibitors as cognitive enhancers in fear, anxiety and trauma therapy: where do we stand?

Authors:  Nigel Whittle; Nicolas Singewald
Journal:  Biochem Soc Trans       Date:  2014-04       Impact factor: 5.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.